Drug Research
Price Negotiations For 10 US Prescription Drugs To Be Shared
A senior Biden White House official said on January 11 that the U.S. administration will provide a list of the ten prescription pharmaceuticals for which it intends to negotiate prices on September 1 and the costs a year later.
The...
News
Addressing Inflation A Prime Concern For Global Pharma
As the high inflation threat is on the subsiding verge, the second-round effects may not go away quickly. Pharma may have to go through a difficult path with slowly falling inflation in regions apart from the US.
Inflation, which has...
Drug Research
Antibiotics Shortage Challenge- A Growing Concern For Europe
According to Stella Kyriakides, the EU Health Commissioner, the thought about changes to EU pharmaceutical law shall have robust obligations for medicine supply and also earlier shortage notifications.
She was speaking at the European Parliament session, where she opined that...
IT & Data Management
Aortic Stability Evaluation To Find Patients At High Risk
According to a recent study conducted in collaboration by the University of Eastern Finland and Kuopio University Hospital, patients with ascending aortic dilatation are more likely to experience pathological changes in the aortic wall when wall shear stress values...
Drug Research
FDA Wraps Up The REMS Standards For Prescription Medicines
The FDA's Final Guidance on REMS programmes for prescription medications, has just been published. The document is officially titled Format and Content of a REMS Document: Guidance for Industry.
The FDA may demand a risk management strategy known as REMS,...
Drug Research
United States-Switzerland Strike A Drug Inspection Accord
The US and Switzerland have agreed to a Mutual Recognition Agreement (MRA) on pharmaceutical Good Manufacturing Practices (GMP).
The US Food and Drug Administration (FDA) and the Swiss Agency for Therapeutic Products (Swissmedic) will be able to utilize each other's...
News
A Sizeable Increase In Healthcare Deals Anticipated In 2023
Pharma companies with plenty of cash were on one side of a $200 billion patent cliff. On the other hand, there were a lot of smaller biotech companies that were cash-strapped and offering assets at a discount. These companies'...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read